M. Michalska

发表

Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database

J. Best, S. Unizony, A. Kong, 2019, Rheumatology and Therapy.

Costs of Disease Relapses Among Individuals with Granulomatosis, with Polyangiitis, or Microscopic Polyangiitis in the United States

J. Best, A. Kong, M. Michalska, 2018, Rheumatology and Therapy.

Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy

J. Kremer, C. Peterfy, W. Reiss, 2020, The Journal of Rheumatology.

Low immunogenicity of tocilizumab in patients with rheumatoid arthritis

M. Genovese, K. Stubenrauch, A. Ogata, 2016, Annals of the rheumatic diseases.

Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study

A. Kivitz, E. Olech, M. Michalska, 2016, Rheumatology and Therapy.

SAT0167 COMPARISON OF THE EFFICACY AND TOLERABILITY OF TOCILIZUMAB, SARILUMAB, AND SIRUKUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: A BAYESIAN NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

J. Kremer, C. Peterfy, W. Reiss, 2022 .

Osteogenic protein 1 in synovial fluid from patients with rheumatoid arthritis or osteoarthritis: relationship with disease and levels of hyaluronan and antigenic keratan sulfate

E. Thonar, M. Lenz, J. Block, 2006, Arthritis research & therapy.

Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis

R. Yeung, A. Hersh, P. Brunetta, 2021, Arthritis & rheumatology.

Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab

J. Kremer, W. Reiss, C. Birchwood, 2018, Arthritis & rheumatology.

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis

V. Strand, G. Burmester, J. Smolen, 2018, RMD Open.

Drug-induced systemic lupus erythematosus associated with etanercept therapy

Najia Shakoor, J. Block, N. Shakoor, 2002, The Lancet.

Treatment Patterns, Disease Burden, and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Real-World, Electronic Health Record-Based Study of Patients in Clinical Practice

S. Mohan, M. Michalska, Shalini V. Mohan, 2021, Rheumatology and Therapy.

Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials

V. Strand, A. Kavanaugh, C. Gabay, 2017, RMD Open.

Subcutaneous administration of CAMPATH-1H: clinical and biological outcomes.

T. Schnitzer, L. Thurmond, J. Johnston, 1997, The Journal of rheumatology.

Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis

J. Best, I. Abbass, A. Kong, 2019, ClinicoEconomics and outcomes research : CEOR.

AB0448 Patient-reported outcomes following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab: results from a randomised controlled trial

J. Best, W. Reiss, C. Birchwood, 2018, Rheumatoid arthritis – biological DMARDs.

OP0105 Long-term safety of tocilizumab from large clinical trial and postmarketing populations

C. Birchwood, M. Michalska, J. Pei, 2017 .

FRI0222 Sustained response following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab: results from a randomized controlled trial (COMP-ACT)

W. Reiss, C. Birchwood, W. Rigby, 2017 .

SAT0168 Mri results following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab: results from a randomized controlled trial

W. Reiss, C. Birchwood, M. Michalska, 2018, Saturday, 16 JUNE 2018.